This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Securities Arbitration Law Firm Of Klayman & Toskes Investigates Claims On Behalf Of Investors Who Sustained Losses In The UBS Willow Fund, L.L.C.

The Securities Arbitration Law Firm of Klayman & Toskes (“K&T”),, announced today that it is investigating the sales practices of brokerage firms, including UBS Financial Services (NYSE: UBS), who sold the UBS Willow Fund to their customers. Last month, a class action lawsuit was filed on behalf of investors in the UBS Willow Fund. Eligible class members are encouraged to explore all of their legal options, including filing an individual securities arbitration claim against their full service brokerage firm who sold them the Fund.

The UBS Willow Fund is a private hedge fund, which was formed in 2000. In October of 2012 investors were notified that the Fund would be liquidated. While many investors were advised that the Fund was a safe, low risk product, the Fund has declined about 80%. Accordingly, K&T is investigating whether brokerage firms adequately disclosed the risks associated with the product, as well as whether investors’ portfolios were over-concentrated in the Fund. K&T has been contacted by Willow Fund investors who purchased the product from UBS Financial Services, and are preparing to file securities arbitration claims on their behalf.

Investors who have sustained losses in the UBS Willow Fund can contact K&T to explore their legal rights and options. The attorneys at K&T are dedicated to pursuing claims on behalf of investors who have suffered investment losses. K&T, an experienced, qualified and nationally recognized securities litigation law firm, practices exclusively in the field of securities arbitration and litigation. It continues its representation of investors throughout the world in securities arbitration and litigation matters against major Wall Street brokerage firms.

If you wish to discuss this announcement or have investment losses of $100,000 or more in the UBS Willow Fund, please contact Steven D. Toskes, Esquire or Jahan K. Manasseh, Esquire of Klayman & Toskes, P.A., at 888-997-9956 or visit us on the web at

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs